FHA
ITOS

First Horizon Advisors’s iTeos Therapeutics ITOS Stock Holding History

First Horizon Advisors’s Portfolio ITOS Stock Details ITOS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-35
Closed – – 2490
2022
Q3 		$0 Buy
+35
New +$806 ﹤0.01% 2361

Other funds holding ITOS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
MAM
MPM Asset Management Boston, Massachusetts $44.5M AUM 47.28% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.29B AUM 141.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

First Horizon Advisors's ITOS Position: Q4 2022 in Review

First Horizon Advisors sold out of iTeos Therapeutics (ITOS) in Q4 2022, closing a stake of 35 shares.

First Horizon Advisors first reported a position in ITOS in Q3 2022 and held it in 1 quarter. The position peaked at $0 in Q3 2022. 146 funds tracked by Wall St. Rank hold ITOS as of Q4 2022.

  • First Horizon Advisors reported no remaining iTeos Therapeutics position as of Q4 2022 after selling out during the quarter.
  • First Horizon Advisors sold 35 iTeos Therapeutics shares in Q4 2022.
  • First Horizon Advisors first reported a position in iTeos Therapeutics in Q3 2022 and held it in 1 quarter.
  • First Horizon Advisors's iTeos Therapeutics position peaked at $0 in Q3 2022.
  • 146 funds tracked by Wall St. Rank held iTeos Therapeutics as of Q4 2022.

Based on First Horizon Advisors's 13F filing for Q4 2022, filed 10 Feb 2023.